Berit Markevärn

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums et al. · Leukemia · 2016 · 247 citations · Full text

Medicine, Hematology, Immunology +14

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

Magnus Björkholm, Åsa Rangert Derolf, Malin Hultcrantz et al. · Journal of Clinical Oncology · 2011 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text

Medicine, Hematology, Oncology +10

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström et al. · Blood · 2013 · 127 citations

Medicine, Oncology, Pharmacotherapy +13

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

Anders Wåhlin, Berit Markevärn, Irina Golovleva et al. · British Journal of Haematology · 2001 · 88 citations

Medicine, Hematology, Oncology +10